Novomer, Inc.

Novomer highlighted as #1 in GreanBeat's 2009’s top 9 forward-looking cleantech investments

Novomer highlighted as #1 in GreanBeat's 2009’s top 9 forward-looking cleantech investments

December 31, 2009

1. Novomer — In April, Novomer, a company that sequesters carbon dioxide emissions from coal-fired plants and other sources in biodegradable plastic consumer products, brought in $14 million ... has the opportunity to capture a vast amount of carbon that would otherwise be released into the atmosphere while cheaply making plastic products that don’t require as much petroleum. It’s basically greening two businesses at once.

T2 Biosystems, Inc.

T2 BioSystems Appoints Ken Toso Vice President, Product Development

T2 BioSystems Appoints Ken Toso Vice President, Product Development

January 6, 2010

Company Preparing for Commercial Evaluation and Launch

Ensemble Therapeutics Corporation

Ensemble Discovery Initiates Collaboration with Pfizer to Develop Novel Drugs against Protein-Protein Interaction Targets

Ensemble Discovery Initiates Collaboration with Pfizer to Develop Novel Drugs against Protein-Protein Interaction Targets

January 6, 2010

Second Major Alliance Validates Ensemble Leadership in New Therapeutic Space

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Discovery today announced the initiation of a strategic alliance with Pfizer Inc. (NYSE: PFE) to discover and develop drug candidates of a novel class against a number of high-value pharmaceutical targets.

Mascoma Corporation

Mascoma Appoints William J. Brady as Chief Executive Officer

Mascoma Appoints William J. Brady as Chief Executive Officer

January 7, 2010

New Leadership Reflects Company’s Transition into Commercial Operations

Lebanon, New Hampshire – January 7, 2010: Mascoma Corporation today announced the appointment of William J. Brady as the new Chief Executive Officer, effective immediately. Mr. Brady will also join the Boards of Directors of Mascoma and Frontier Renewable Resources, LLC. With twenty-three years of experience at Cabot Corporation, a chemical industry leader, Bill is poised to lead Mascoma into full commercial operations.

BIND Therapeutics, Inc.

BIND Biosciences Appoints Scott Minick as President and CEO

BIND Biosciences Appoints Scott Minick as President and CEO

January 11, 2010

CAMBRIDGE, Mass. - (Business Wire) BIND Biosciences announced today the appointment of Scott Minick as President and CEO. Mr. Minick was formerly a Managing Director at ARCH Venture Partners, a major BIND investor, and previously the President and COO of SEQUUS Pharmaceuticals/Liposome Technology Inc., where he led the company during its 1995 FDA approval and successful commercial launch of the leading oncology drug, Doxil (liposomal doxorubicin). SEQUUS was subsequently acquired by ALZA for $580 MM.

BIND Therapeutics, Inc.

BIND Biosciences, Inc. Closes $11M Series C Financing Round

BIND Biosciences, Inc. Closes $11M Series C Financing Round

January 14, 2010

High-Precision Therapeutics through Medicinal Nanoengineering™

VisEn Medical, Inc.

VisEn Launches New Cat B 680 FAST™ Fluorescence Molecular Imaging Agent

VisEn Launches New Cat B 680 FAST™ Fluorescence Molecular Imaging Agent

January 19, 2010

Extends VisEn’s Leading Fluorescence Molecular Imaging Agent Portfolio to Enable Expanded Readouts of Key Protease Biomarkers in Research and Drug Development

BEDFORD, MA (January 19, 2010)—VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 680 FAST™ imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo.

Helicos BioSciences Corporation

Helicos BioSciences Announces the Sale of a Helicos® Genetic Analysis System to the Turku Centre for Biotechnology

Helicos BioSciences Announces the Sale of a Helicos® Genetic Analysis System to the Turku Centre for Biotechnology

January 19, 2010

CAMBRIDGE, Mass., Jan 19, 2010 (BUSINESS WIRE) -- Helicos BioSciences Corporation (NASDAQ: HLCS), today announced the sale of a Helicos® Genetic Analysis System to the Turku Centre for Biotechnology in Turku, Finland. The center, led by Dr. Riitta Lahesmaa, is a joint facility of the University of Turku and Åbo Akademi University.

"We are very excited by our acquisition of a Helicos System, as it will allow us to perform novel experiments using single molecule sequencing technology." said Riitta Lahesmaa, Director of the center.

Joule Unlimited, Inc.

Joule Biotechnologies Secures Pilot Site for Renewable Solar Fuel

Joule Biotechnologies Secures Pilot Site for Renewable Solar Fuel

January 20, 2010

CAMBRIDGE, Mass.--Joule Biotechnologies, Inc. today announced the signing of a lease agreement to build its first pilot plant in Leander, Texas, where the company will further develop and test its transformative system for the production of renewable solar fuels. Powered by sunlight and free of costly feedstocks or processing steps, the system is being engineered to eclipse the productivities, scale and cost efficiencies of biomass-dependent approaches. The site was chosen in part for its high solar insolation and logistically convenient location.

Novomer, Inc.

DSM and Novomer to Develop First CO2-based Resin for Coatings

DSM and Novomer to Develop First CO2-based Resin for Coatings

January 21, 2010

HEERLEN, THE NETHERLANDS -- (MARKET WIRE) -- 01/21/10 -- Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, and Novomer Inc., based in Waltham (Massachusetts, United States), today announce that they have signed an agreement to jointly develop a revolutionary coating resin using carbon dioxide (CO2) as a raw material.